Annexon, Inc. (NASDAQ:ANNX) Director Acquires $19,424.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson purchased 3,200 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $6.07 per share, with a total value of $19,424.00. Following the completion of the acquisition, the director now directly owns 3,200 shares of the company’s stock, valued at $19,424. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Annexon Price Performance

ANNX stock opened at $6.07 on Friday. The company’s 50 day simple moving average is $5.74 and its 200-day simple moving average is $3.95. The firm has a market capitalization of $546.46 million, a PE ratio of -3.41 and a beta of 1.14. Annexon, Inc. has a 12 month low of $1.57 and a 12 month high of $8.40.

Institutional Trading of Annexon

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its position in shares of Annexon by 31.3% in the first quarter. Tower Research Capital LLC TRC now owns 7,992 shares of the company’s stock valued at $31,000 after purchasing an additional 1,903 shares during the last quarter. Bank of America Corp DE boosted its position in Annexon by 29.7% during the fourth quarter. Bank of America Corp DE now owns 8,938 shares of the company’s stock worth $46,000 after acquiring an additional 2,049 shares during the last quarter. Quantbot Technologies LP boosted its position in Annexon by 630.8% during the first quarter. Quantbot Technologies LP now owns 9,500 shares of the company’s stock worth $25,000 after acquiring an additional 8,200 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Annexon during the fourth quarter worth approximately $46,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Annexon during the fourth quarter worth approximately $57,000.

Analysts Set New Price Targets

Several research firms recently issued reports on ANNX. Bank of America increased their price target on shares of Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. JPMorgan Chase & Co. upped their target price on shares of Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, April 1st. Wells Fargo & Company upped their target price on shares of Annexon from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Wednesday, April 3rd. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Wednesday, March 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon has a consensus rating of “Buy” and a consensus price target of $14.43.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.